よむ、つかう、まなぶ。
参考資料14 高齢者がん医療Ｑ＆Ａ総論（厚生労働科学研究「高齢者がん診療指針策定に必要な基盤整備に関する研究」） (114 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_28073.html |
| 出典情報 | がん対策推進協議会（第82回 9／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
15) Poggio ED et al. Demographic and clinical characteristics associated with glomerular
filtration rates in living kidney donors. Kidney Int. 2009;75:1079-1087
16) Drusano GL et al. Commonly used methods of estimating creatinine clearance are
inadequate for elderly debilitated nursing home patients. J Am Geriatr Soc. 1988;36:437441
17) Shah SR et al. Risk of renal failure in cancer patients with bone metastasis treated
with renally adjusted zoledronic acid. Support Care Cancer. 2012;20:87-93
18) Himelstein AL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid
on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial.
JAMA. 2017;317:48-58
19) Block GA et al. A single-dose study of denosumab in patients with various degrees of renal
impairment. J Bone Miner Res. 2012；27：1471-1479
20) Hanamura M et al. Risk factors contributing to the development of hypocalcemia after
zoledronic acid administration in patients with bone metastases of solid tumor.
Biol Pharm Bull. 2010；33：721-724
21) Ng YH et al. Femoral shaft fractures in the elderly-role of prior bisphosphonate therapy.
Injury. 2011;42:702-706
22) Bone HG et al. Effects of denosumab treatment and discontinuation on bone
mineraldensity and bone turnover markers in postmenopausal women with low bone mass.
J Clin Endocrinol Metab. 2011;96:972-980
23) Aubry-Rozier B et al. Severe spontaneous vertebral fractures after denosuma
discontinuation: three case reports. Osteoporos Int. 2016;27:1923-1925
106
filtration rates in living kidney donors. Kidney Int. 2009;75:1079-1087
16) Drusano GL et al. Commonly used methods of estimating creatinine clearance are
inadequate for elderly debilitated nursing home patients. J Am Geriatr Soc. 1988;36:437441
17) Shah SR et al. Risk of renal failure in cancer patients with bone metastasis treated
with renally adjusted zoledronic acid. Support Care Cancer. 2012;20:87-93
18) Himelstein AL et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid
on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial.
JAMA. 2017;317:48-58
19) Block GA et al. A single-dose study of denosumab in patients with various degrees of renal
impairment. J Bone Miner Res. 2012；27：1471-1479
20) Hanamura M et al. Risk factors contributing to the development of hypocalcemia after
zoledronic acid administration in patients with bone metastases of solid tumor.
Biol Pharm Bull. 2010；33：721-724
21) Ng YH et al. Femoral shaft fractures in the elderly-role of prior bisphosphonate therapy.
Injury. 2011;42:702-706
22) Bone HG et al. Effects of denosumab treatment and discontinuation on bone
mineraldensity and bone turnover markers in postmenopausal women with low bone mass.
J Clin Endocrinol Metab. 2011;96:972-980
23) Aubry-Rozier B et al. Severe spontaneous vertebral fractures after denosuma
discontinuation: three case reports. Osteoporos Int. 2016;27:1923-1925
106